3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
1
Disease
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
Dexamethasone
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tislelizumab
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
lortalamine
1
gossypol acetic acid
1
daratumumab
1
aflibercept
1
Prednisone
1
Oncolytic Virotherapy
1
Octreotide
1
Mitomycin
1
Mammography
1
Lenalidomide
1
Ipilimumab
1
Drug Delivery Systems
1
Docetaxel
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
Bevacizumab
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease
×
Diagnosis, Computer-Assisted
×
Clear all
NCT06221397
2026-03-16
LEGIT_MC_EVCDA
AI Labs Group S.L
Completed
105 enrolled
15 charts